The government of Brazil has officially approved the world’s first single-dose dengue vaccine, marking a breakthrough in global efforts to combat the mosquito-borne disease. According to medical reports, the vaccine developed entirely in Brazil has been authorized for use in individuals aged 12 to 59 who have previously been infected with dengue.
Officials stated that the approval was granted after eight years of extensive clinical trials, during which the vaccine consistently demonstrated high efficacy and safety. The vaccine was produced in collaboration with a Chinese pharmaceutical company and utilizes a live attenuated dengue virus, similar to the mechanism used in polio vaccines to help the body develop immunity.
Trial data revealed that the single-dose vaccine reduces overall dengue symptoms by up to 74 percent, while severe and complicated symptoms are reduced by as much as 84 percent. Experts say these results are highly promising and represent a significant advancement in dengue prevention.
The vaccine has been declared safe for individuals between 12 and 59 years old, and Brazilian authorities have indicated that additional versions for younger children and older adults will be developed soon. Initially, the vaccine will be available only within Brazil, but global distribution is expected in later stages.
Before this development, the World Health Organization (WHO) had approved only one dengue vaccine worldwide, which requires two doses administered three months apart. Brazil’s new single-dose vaccine is therefore being considered a landmark achievement in medical science.
